Recombinant Rat KCNB1 Protein
| 货号： | GXP81109 |
|---|---|
| Swiss Prot： | P15387 |
| 种属： | Rat |
| 表达宿主： | E. Coli / 293F |
| 表达区间： | 1–857aa |
| 标签： | Customize |
| 纯度： | >90% |
| 内毒素： | < 1.0 EU/μg / < 0.1 EU/μg |
价格：¥2580
货期：3-4周/weeks
规格：
说明书：
产品详情
| 产品名称： | Recombinant Rat KCNB1 Protein |
|---|---|
| 别名： | Kcnb1 |
| 货号： | GXP81109 |
| Swiss Prot： | P15387 |
| 种属： | Rat |
| 表达宿主： | E. Coli / 293F |
| 表达区间： | 1–857aa |
| 标签： | Customize |
| 纯度： | >90% |
| 实际分子量： | Depends On Tags |
| 内毒素： | < 1.0 EU/μg / < 0.1 EU/μg |
| 无载体： | Yes |
| 无动物源： | Yes |
| 制剂： | Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4.Contact us for customized product form or formulation. |
| 描述： | Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain, but also in the pancreas and cardiovascular system. Contributes to the regulation of the action potential (AP) repolarization, duration and frequency of repetitive AP firing in neurons, muscle cells and endocrine cells and plays a role in homeostatic attenuation of electrical excitability throughout the brain (PubMed:10024359, PubMed:10618149, PubMed:12451110, PubMed:17379638, PubMed:19276663, PubMed:23878373). Also plays a role in the regulation of exocytosis independently of its electrical function (PubMed:20484665). Forms tetrameric potassium-selective channels through which potassium ions pass in accordance with their electrochemical gradient. The channel alternates between opened and closed conformations in response to the voltage difference across the membrane. Homotetrameric channels mediate a delayed-rectifier voltage-dependent outward potassium current that display rapid activation and slow inactivation in response to membrane depolarization (PubMed:12560340, PubMed:1875913, PubMed:2206531, PubMed:2770868, PubMed:8083226, PubMed:8978827, PubMed:9351973, PubMed:9565597). Can form functional homotetrameric and heterotetrameric channels that contain variable proportions of KCNB2; channel properties depend on the type of alpha subunits that are part of the channel (PubMed:20202934). Can also form functional heterotetrameric channels with other alpha subunits that are non-conducting when expressed alone, such as KCNF1, KCNG1, KCNG3, KCNG4, KCNH1, KCNH2, KCNS1, KCNS2, KCNS3 and KCNV1, creating a functionally diverse range of channel complexes (PubMed:8670833, PubMed:8980147, PubMed:9079713, PubMed:9305895, PubMed:9362476, PubMed:9696692). Heterotetrameric channel activity formed with KCNS3 show increased current amplitude with the threshold for action potential activation shifted towards more negative values in hypoxic-treated pulmonary artery smooth muscle cells (PubMed:9362476). Channel properties are also modulated by cytoplasmic ancillary beta subunits such as AMIGO1, KCNE1, KCNE2 and KCNE3, slowing activation and inactivation rate of the delayed rectifier potassium channels (PubMed:12954870, PubMed:19219384). In vivo, membranes probably contain a mixture of heteromeric potassium channel complexes, making it difficult to assign currents observed in intact tissues to any particular potassium channel family member. Major contributor to the slowly inactivating delayed-rectifier voltage-gated potassium current in neurons of the central nervous system, sympathetic ganglion neurons, neuroendocrine cells, pancreatic beta cells, cardiomyocytes and smooth muscle cells (PubMed:10024359, PubMed:10414968, PubMed:10618149, PubMed:11463864, PubMed:12127166, PubMed:12403834, PubMed:12451110, PubMed:12621036, PubMed:12807875, PubMed:12832499, PubMed:12954870, PubMed:15195093, PubMed:15322114, PubMed:16407566, PubMed:17301173, PubMed:17379638, PubMed:18167541, PubMed:18463252, PubMed:19276663, PubMed:20484665, PubMed:21518833, PubMed:22411134, PubMed:23878373, PubMed:9362476, PubMed:9616203). Mediates the major part of the somatodendritic delayed-rectifier potassium current in hippocampal and cortical pyramidal neurons and sympathetic superior cervical ganglion (CGC) neurons that acts to slow down periods of firing, especially during high frequency stimulation (PubMed:10618149, PubMed:12451110, PubMed:16319318, PubMed:16917065, PubMed:17379638, PubMed:19276663, PubMed:23878373). Plays a role in the induction of long-term potentiation (LTP) of neuron excitability in the CA3 layer of the hippocampus (By similarity). Contributes to the regulation of glucose-induced action potential amplitude and duration in pancreatic beta cells, hence limiting calcium influx and insulin secretion (PubMed:11463864). Plays a role in the regulation of resting membrane potential and contraction in hypoxia-treated pulmonary artery smooth muscle cells (PubMed:9616203). May contribute to the regulation of the duration of both the action potential of cardiomyocytes and the heart ventricular repolarization QT interval (By similarity). Contributes to the pronounced pro-apoptotic potassium current surge during neuronal apoptotic cell death in response to oxidative injury (PubMed:12832499, PubMed:16273079, PubMed:17360683, PubMed:19077057, PubMed:19622611, PubMed:24928958). May confer neuroprotection in response to hypoxia/ischemic insults by suppressing pyramidal neurons hyperexcitability in hippocampal and cortical regions (PubMed:16319318). Promotes trafficking of KCNG3, KCNH1 and KCNH2 to the cell surface membrane, presumably by forming heterotetrameric channels with these subunits (By similarity). Plays a role in the calcium-dependent recruitment and release of fusion-competent vesicles from the soma of neurons, neuroendocrine and glucose-induced pancreatic beta cells by binding key components of the fusion machinery in a pore-independent manner (PubMed:11463864, PubMed:17301173, PubMed:18167541, PubMed:20484665, PubMed:22411134). {ECO:0000250|UniProtKB:Q03717, ECO:0000269|PubMed:10024359, ECO:0000269|PubMed:10414968, ECO:0000269|PubMed:10618149, ECO:0000269|PubMed:11463864, ECO:0000269|PubMed:12127166, ECO:0000269|PubMed:12403834, ECO:0000269|PubMed:12451110, ECO:0000269|PubMed:12560340, ECO:0000269|PubMed:12621036, ECO:0000269|PubMed:12807875, ECO:0000269|PubMed:12832499, ECO:0000269|PubMed:12954870, ECO:0000269|PubMed:15195093, ECO:0000269|PubMed:15322114, ECO:0000269|PubMed:16273079, ECO:0000269|PubMed:16319318, ECO:0000269|PubMed:16407566, ECO:0000269|PubMed:16917065, ECO:0000269|PubMed:17301173, ECO:0000269|PubMed:17360683, ECO:0000269|PubMed:17379638, ECO:0000269|PubMed:18167541, ECO:0000269|PubMed:18463252, ECO:0000269|PubMed:1875913, ECO:0000269|PubMed:19077057, ECO:0000269|PubMed:19219384, ECO:0000269|PubMed:19276663, ECO:0000269|PubMed:19622611, ECO:0000269|PubMed:20202934, ECO:0000269|PubMed:20484665, ECO:0000269|PubMed:21518833, ECO:0000269|PubMed:2206531, ECO:0000269|PubMed:22411134, ECO:0000269|PubMed:23878373, ECO:0000269|PubMed:24928958, ECO:0000269|PubMed:2770868, ECO:0000269|PubMed:8083226, ECO:0000269|PubMed:8670833, ECO:0000269|PubMed:8978827, ECO:0000269|PubMed:8980147, ECO:0000269|PubMed:9079713, ECO:0000269|PubMed:9305895, ECO:0000269|PubMed:9351973, ECO:0000269|PubMed:9362476, ECO:0000269|PubMed:9565597, ECO:0000269|PubMed:9616203, ECO:0000269|PubMed:9696692}. |
| 活性测试： | Not Test |
| 复溶： |
Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles. 收到重组蛋白产品之后请检查蛋白冻干粉末是否贴于瓶底，如果粉末浮起，开盖之前请先低温离心。将蛋白用说明书中指定的缓冲液复溶至0.1-0.5 mg/mL（请注意蛋白复溶浓度不能低于0.1 mg/mL），室温平衡5-10 min保证充分溶解，复溶过程中请不要剧烈涡旋及吹打蛋白溶液。如需长期储存，建议复溶时添加载体蛋白或者稳定剂（如0.1% BSA, 5% HSA, 10% FBS 或者 5% 海藻糖），同时将复溶后的蛋白溶液按照需求进行分装，储存于-20°C至-80°C，随取随用，避免反复冻融。 |
| 储存： |
Store at -20℃.Store the lyophilized protein at -20℃ to -80 ℃ up to 1 year from the date of receipt. After reconstitution, the protein solution is stable at -20℃ for 3 months, at 2-8℃ for up to 1 week. 未开盖的干粉蛋白在 -20°C至-80°C可保存12个月； 复溶之后，蛋白溶液在-20°C及以下可保存3个月，在2-8℃可保存1周。 |
